MedPath

Bupivacaine

Generic Name
Bupivacaine
Brand Names
Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal
Drug Type
Small Molecule
Chemical Formula
C18H28N2O
CAS Number
38396-39-3
Unique Ingredient Identifier
Y8335394RO

Overview

Bupivacaine is a widely used local anesthetic agent.

Background

Bupivacaine is a widely used local anesthetic agent.

Indication

As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair. Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions

  • Acute Gouty Arthritis
  • Adrenocortical Insufficiency
  • Alopecia Areata (AA)
  • Ankylosing Spondylitis (AS)
  • Berylliosis
  • Bullous dermatitis herpetiformis
  • Congenital Adrenal Hyperplasia (CAH)
  • Congenital Hypoplastic Anemia
  • Dermatomyositis (DM)
  • Discoid Lupus Erythematosus (DLE)
  • Edema of the cerebrum
  • Epicondylitis
  • Hemolytic Anemia
  • Hypercalcemia caused by Cancer
  • Keloids Scars
  • Leukemias
  • Mycosis Fungoides (MF)
  • Necrobiosis lipoidica diabeticorum
  • Ocular Inflammation
  • Ophthalmia, Sympathetic
  • Osteoarthritis (OA)
  • Pain, Labor
  • Polymyositis
  • Postoperative pain
  • Psoriatic Arthritis
  • Psoriatic plaque
  • Pure Red Cell Aplasia
  • Regional Enteritis
  • Rheumatoid Arthritis
  • Secondary thrombocytopenia
  • Stevens-Johnson Syndrome
  • Synovitis
  • Systemic Lupus Erythematosus
  • Temporal Arteritis
  • Trichinosis
  • Tuberculous Meningitis
  • Ulcerative Colitis
  • Uveitis
  • Acute Bursitis
  • Acute Idiopathic Nephrotic Syndrome
  • Acute Lupus Erythematosus
  • Acute Multiple sclerosis
  • Acute Rheumatic heart disease, unspecified
  • Acute nonspecific tenosynovitis
  • Cystic tumors of aponeurosis
  • Cystic tumors of tendon
  • Disseminated Pulmonary Tuberculosis (TB)
  • Exfoliative erythroderma
  • Inflammatory lesions of granuloma annulare
  • Inflammatory lesions of lichen planus
  • Inflammatory lesions of lichen simplex
  • Non-suppurative Thyroiditis
  • Permphigus
  • Severe Allergic Reactions

FDA Approved Products

Bupivacaine hydrochloride
Manufacturer:Somerset Therapeutics, LLC
Route:INFILTRATION, PERINEURAL
Strength:5 mg in 1 mL
Approved: 2023/09/19
NDC:70069-753
Bupivacaine HCl
Manufacturer:Xellia Pharmaceuticals USA LLC
Route:EPIDURAL, PERINEURAL, INTRACAUDAL
Strength:5 mg in 1 mL
Approved: 2023/06/09
NDC:70594-118
Bupivacaine Hydrochloride
Manufacturer:Eugia US LLC
Route:INTRACAUDAL, EPIDURAL
Strength:5 mg in 1 mL
Approved: 2023/07/24
NDC:55150-169
Bupivacaine HCl
Manufacturer:Xellia Pharmaceuticals USA LLC
Route:EPIDURAL, PERINEURAL, INTRACAUDAL
Strength:2.5 mg in 1 mL
Approved: 2023/06/09
NDC:70594-114
SENSORCAINE MPF
Manufacturer:Fresenius Kabi USA, LLC
Route:EPIDURAL, RETROBULBAR
Strength:7.5 mg in 1 mL
Approved: 2023/04/30
NDC:63323-472

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath